Anavex Life Sciences Corp (AVXL)

[Investor2014]

Attila, that together with the hiring of Fadiran could well be pointing to a Master Protocol with a considerable number of trials across the many A2-73 indications we know about kicking of.

"Dr. Fadiran has an accomplished track record of working within the FDA,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “His depth of experience makes him an excellent choice to manage the considerable number of regulatory filings that Anavex has planned"

Of course more trials means more funding required. Would be good to see that nut cracked with minimum dilution.

Minimum dilution though should be seen in perspective of the considerable revenue potential, if that is we end up with approval!

Just remember that once we see the first approval, likely in Rett, Anavex will become a revenue generating company.